Compile Data Set for Download or QSAR
Report error Found 72 Enz. Inhib. hit(s) with all data for entry = 8702
TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287599(US9567341, Compound C-7 | BDBM413607)
Affinity DataIC50: 14nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287604(US9567341, Compound C-175 | US9968610, Compound C-...)
Affinity DataIC50: 22nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287604(US9567341, Compound C-175 | US9968610, Compound C-...)
Affinity DataIC50: 22nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287587(US9567341, Compound C-3 | US9968610, Compound C-3 ...)
Affinity DataIC50: 22nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287604(US9567341, Compound C-175 | US9968610, Compound C-...)
Affinity DataIC50: 22nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287587(US9567341, Compound C-3 | US9968610, Compound C-3 ...)
Affinity DataIC50: 22nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287587(US9567341, Compound C-3 | US9968610, Compound C-3 ...)
Affinity DataIC50: 22nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287603(BDBM617007 | US9567341, Compound C-179 | BDBM41361...)
Affinity DataIC50: 23nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287603(BDBM617007 | US9567341, Compound C-179 | BDBM41361...)
Affinity DataIC50: 23nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280739(US10030026, Compound LX-1 | US10221182, Compound L...)
Affinity DataIC50: 24nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280739(US10030026, Compound LX-1 | US10221182, Compound L...)
Affinity DataIC50: 24nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287601(US9567341, Compound C-12 | US10420768, Compound C-...)
Affinity DataIC50: 24nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287605(US9567341, Compound C-176 | US10420768, Compound C...)
Affinity DataIC50: 26nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287606(US9567341, Compound C-177 | US10420768, Compound C...)
Affinity DataIC50: 27nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287589(US9567341, Compound C-5 | US9968610, Compound C-5 ...)
Affinity DataIC50: 30nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287589(US9567341, Compound C-5 | US9968610, Compound C-5 ...)
Affinity DataIC50: 30nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287589(US9567341, Compound C-5 | US9968610, Compound C-5 ...)
Affinity DataIC50: 30nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287598(US9567341, Compound C-6 | BDBM413606 | US11752155,...)
Affinity DataIC50: 31nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287588(US9567341, Compound C-4 | US9968610, Compound C-4 ...)
Affinity DataIC50: 35nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287588(US9567341, Compound C-4 | US9968610, Compound C-4 ...)
Affinity DataIC50: 35nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287600(US9567341, Compound C-11 | US10420768, Compound C-...)
Affinity DataIC50: 43nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287592(US9567341, Compound C-17 | US10420768, Compound C-...)
Affinity DataIC50: 44nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287596(US9567341, Compound C-127 | US9968610, Compound C-...)
Affinity DataIC50: 45nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287596(US9567341, Compound C-127 | US9968610, Compound C-...)
Affinity DataIC50: 45nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287596(US9567341, Compound C-127 | US9968610, Compound C-...)
Affinity DataIC50: 45nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287590(US9567341, Compound C-16 | US10420768, Compound C-...)
Affinity DataIC50: 47nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287602(US9567341, Compound C-178 | US9968610, Compound C-...)
Affinity DataIC50: 64nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287602(US9567341, Compound C-178 | US9968610, Compound C-...)
Affinity DataIC50: 64nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287591(US9567341, Compound C-18 | US10420768, Compound C-...)
Affinity DataIC50: 84nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287594(US9567341, Compound C-230 | US9968610, Compound C-...)
Affinity DataIC50: 88nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287594(US9567341, Compound C-230 | US9968610, Compound C-...)
Affinity DataIC50: 88nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287597(US9567341, Compound C-128 | US9968610, Compound C-...)
Affinity DataIC50: 89nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287597(US9567341, Compound C-128 | US9968610, Compound C-...)
Affinity DataIC50: 89nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287586(US9567341, Compound C-2 | US10420768, Compound C-2)
Affinity DataIC50: 124nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287593(US9567341, Compound C-47 | US10420768, Compound C-...)
Affinity DataIC50: 140nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280723(N-(1-(2,2-difluoro-2-(pyridin-2-yl)ethyl)piperidin...)
Affinity DataIC50: 159nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCytochrome P450 2D6(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280739(US10030026, Compound LX-1 | US10221182, Compound L...)
Affinity DataIC50: 1.00E+3nMAssay Description:CYP P450: Inhibitory activities of test compounds on 5 major isoforms of CYP P450 were evaluated by using pooled human liver microsome (HLM, purchase...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCytochrome P450 2D6(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287604(US9567341, Compound C-175 | US9968610, Compound C-...)
Affinity DataIC50: 2.30E+3nMAssay Description:CYP P450: Inhibitory activities of test compounds on 5 major isoforms of CYP P450 were evaluated by using pooled human liver microsome (HLM, purchase...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287604(US9567341, Compound C-175 | US9968610, Compound C-...)
Affinity DataIC50: 4.50E+3nMAssay Description:hERG: The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280739(US10030026, Compound LX-1 | US10221182, Compound L...)
Affinity DataIC50: 4.50E+3nMAssay Description:hERG: The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCytochrome P450 2D6(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287603(BDBM617007 | US9567341, Compound C-179 | BDBM41361...)
Affinity DataIC50: 4.90E+3nMAssay Description:CYP P450: Inhibitory activities of test compounds on 5 major isoforms of CYP P450 were evaluated by using pooled human liver microsome (HLM, purchase...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287596(US9567341, Compound C-127 | US9968610, Compound C-...)
Affinity DataIC50: 6.00E+3nMAssay Description:hERG: The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCytochrome P450 2D6(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287602(US9567341, Compound C-178 | US9968610, Compound C-...)
Affinity DataIC50: 6.70E+3nMAssay Description:CYP P450: Inhibitory activities of test compounds on 5 major isoforms of CYP P450 were evaluated by using pooled human liver microsome (HLM, purchase...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287587(US9567341, Compound C-3 | US9968610, Compound C-3 ...)
Affinity DataIC50: 7.00E+3nMAssay Description:hERG: The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287589(US9567341, Compound C-5 | US9968610, Compound C-5 ...)
Affinity DataIC50: 9.50E+3nMAssay Description:hERG: The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCytochrome P450 2D6(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287596(US9567341, Compound C-127 | US9968610, Compound C-...)
Affinity DataIC50: 1.10E+4nMAssay Description:CYP P450: Inhibitory activities of test compounds on 5 major isoforms of CYP P450 were evaluated by using pooled human liver microsome (HLM, purchase...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287588(US9567341, Compound C-4 | US9968610, Compound C-4 ...)
Affinity DataIC50: 1.14E+4nMAssay Description:hERG: The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCytochrome P450 2D6(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287587(US9567341, Compound C-3 | US9968610, Compound C-3 ...)
Affinity DataIC50: 1.20E+4nMAssay Description:CYP P450: Inhibitory activities of test compounds on 5 major isoforms of CYP P450 were evaluated by using pooled human liver microsome (HLM, purchase...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287594(US9567341, Compound C-230 | US9968610, Compound C-...)
Affinity DataIC50: 1.38E+4nMAssay Description:hERG: The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287597(US9567341, Compound C-128 | US9968610, Compound C-...)
Affinity DataIC50: 2.80E+4nMAssay Description:hERG: The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

Displayed 1 to 50 (of 72 total ) | Next | Last >>
Jump to: